Molecular pathology focuses on the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids. The Association for Molecular Pathology (AMP) is a premier global, non-profit organization serving molecular diagnostic professionals. The AMP has updated its pathology residency curriculum recommendations for 10 critical molecular pathology topics.
The Journal of Molecular Diagnostics published the AMP paper titled, 'A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular Pathology'.
‘The Association for Molecular Pathology (AMP) has updated its pathology residency curriculum recommendations for 10 critical molecular pathology topics.’
AdvertisementDeveloped by a task force of the AMP Training and Education Committee, the latest report is intended to be an update to the original curriculum guidance published by the committee in 1999. The paper provides residency programs with specific recommendations from subject matter experts on 10 major molecular pathology topics: basic molecular pathology goals and laboratory management; basic concepts in molecular biology and genetics; technology; inherited disorders; oncology; infectious diseases; pharmacogenetics; histocompatibility and identity; genomics, and information management.
Charles E. Hill, AMP President and corresponding author of the paper, said, "Molecular pathology is a rapidly evolving area that has the potential to revolutionize the way healthcare is delivered and, as a result, has become an essential and growing component of pathology residency programs. As the voice of molecular diagnostics professionals, AMP remains committed to ensuring medical schools and residency programs are able to incorporate the latest scientific breakthroughs and technological innovations in molecular pathology. This report is another great example of how we are bringing together the subject matter experts to address today's key issues so that pathologists are better equipped to handle the cases tomorrow."